We have used a high performance liquid chromatography assay, which detects chymotryptic cleavage of the phe8-his, bond of angiotensin I to yield angiotensin II, in order to examine human lung mast cells for the presence of chymotryptic activity. Mast cells, purified from human lung by enzymatic dispersion, countercurrent elutriation, and Percoll gradient centrifugation, were lysed or challenged with goat anti-human IgE. In multiple experiments angiotensin II-converting activity was detected in lysates of 10-99% pure mast cell preparations. Regression analysis of net percent release values of histamine and the angiotensin I-converting activity from dose-response experiments demonstrated a correlation between the two parameters, indicating that the chymotrypsin-like enzyme is a constituent of the mast cell secretory granule. The chymotryptic activity was completely inhibited by i0' M phenylmethylsulfonylfluoride but not by 1O-3 M Captopril, and the pH optimum of activity was 7.5-9.5. Gel filtration of released material separated the activity from tryptase and demonstrated an approximate molecular weight of 30-35,000. The mast cell enzyme, like a human skin chymotrypsinlike proteinase, can be distinguished from leukocyte cathepsin G by lack of susceptibility to inhibition by bovine pancreatic trypsin inhibitor. Thus, an enzyme with limited chymotryptic specificity is present in human lung mast cells. The Michaelis constant of the enzyme for angiotensin I of 6.0 X 10-5 M is similar to that of endothelial cell angiotensin-converting enzyme and is consistent with a reaction of physiologic importance.
Introduction
Proteolytic enzymes of mast cells have been studied in cells from a variety of sources, including human lung. The predominant enzyme of the human lung mast cell is tryptase (1, 2) , a molecule with a molecular weight of approximately 145,000, which has been localized to the secretory granule. In contrast, a chymotrypsin-like enzyme (rat mast cell proteinase I or chymase) is the major proteolytic enzyme of the rat serosal mast cell (3, 4) . Similar chymotrypsin-like proteinases have been detected in mastocytoma tissue of dogs (5) , and granule-associated serine neutral proteases have been detected in mouse bone marrowderived mast cells (6) . Recently, a 30-35,000-mol-wt chymotrypsin-like activity has been isolated from high ionic strength extracts of human skin (7) and found in 15-fold higher levels in skin of patients with mastocytosis (7) . Like other enzymes with chymotryptic specificity, the human skin chymotryptic proteinase hydrolyzes the phe8-hisg bond of the decapeptide angiotensin I (Al)' to form angiotensin II (AII) (8, 9) . It is of interest that the human skin enzyme carries out this reaction as efficiently as angiotensin-converting enzyme (ACE) (8) .
Using synthetic substrates, chymotrypsin-like activity has been sought but not identified in preparations of human lung mast cells. Inefficient cleavage of synthetic substrates by a putative chymotrypsin-like enzyme is a possible explanation of this failure. By employing hydrolysis of the phe8-hisg bond of Al as a more sensitive assay, we have detected and partially characterized a chymotrypsin-like enzyme in preparations of purified human lung mast cells. Physicochemical and functional data distinguish this enzyme from tryptase and cathepsin G and show that it is similar to the human skin chymotryptic proteinase.
Methods
(Ile5) Al and (Ile5) All were obtained from Vega Biotechnologies, Inc., Tucson, AZ; des-leu,0-AI, asp-arg-val-tyr, and ile-his-pro-phe from Pen- insula Laboratories, Inc., Belmont, CA; NaCIO4, 85% H3PO4, and CH3CN (high performance liquid chromatography (HPLC) grade) from Fisher Scientific Co., Allied Corp., Pittsburgh, PA; porcine pancreatic a-chymotrypsin (CDi, 49 detectable activity when tested in any of the enzyme assays used in this work.
Mast cell purification. Human lung tissue was obtained from patients undergoing thoracotomy and lung resection, usually for carcinoma of the bronchus or other neoplasms, and mast cells were purified as described previously (10, 1 1). In brief, macroscopically normal lung tissue was dissected free from pleura, bronchi, and blood vessels, minced into 5-10-mg fragments and dispersed into single cell suspensions using two 30-min incubations with pronase and chymopapain followed by two additional 30-min incubations with elastase and collagenase. Mast cells were further purified by countercurrent centrifugation elutriation and by centrifugation over discontinuous gradients of Percoll. Mast cells were quantified at each stage of the purification procedure following staining with Alcian Blue (12) .
Mast cell release and extraction. Mast cell release and extraction procedures were performed in a buffer which contained (grams/liter): piperazine-N-N'bis(2-ethanesulfonic acid), 7.6; NaCl, 6.4; KCl, 0.37; CaCI2, 0.14; MgCl2 6H20, 0.2; glucose, 1.0; 10 N NaOH, 4.2 ml/liter, and human serum albumin, 30 mg/liter (PAGCM). Final pH was adjusted to 7.4. In some dose-response experiments 0.1I% bovine serum albumin was also added to help stabilize the chymotryptic enzyme.
Purified mast cells were suspended in PAGCM at a concentration of 4-8 X 106/mi and were challenged with the appropriate doses of antiIgE (usually in the range of 1-10 Ag/ml) or else with normal goat IgG (as a control). Incubations were performed for 30 min at 370C, at which time cells were sedimented by centrifugation and the supernatant removed. The residual cell pellet was then resuspended to the same cell concentration in PAGCM and was extracted by freeze-thawing (X 4) on dry ice/acetone followed by centrifugation. Whole cell lysates were obtained in the same manner.
Histamine assay. Samples (10 Ml) of the cell suspension and of supernatants after challenge were added to tubes containing I ml of 2% perchloric acid and were diluted as appropriate for determination of histamine, which was measured by an automated fluorometric technique (13) . Histamine release was expressed as net percent of the content of whole cell lysates.
Enzyme assays. Al, AII, and des-leurAI cleavage was measured by an isocratic HPLC assay as described (14) . HPLC was performed on a model 144 system (Beckman Instruments, Inc., Spinco Div., Palo Alto, CA) using a 4.6 X 250 mm-Ultrasphere 5-Mm ODS C18 column (Altex Scientific, Inc., Berkeley, CA) employing an isocratic perchlorate ion pair reverse-phase system using 40% CH3CN and a flow rate of 1.0 ml/ min. Peptides were monitored by absorbance at 200 nm, identified by retention time, and quantified by integration of peak area using an HP 3390a integrating recorder (Hewlett-Packard Co., Palo Alto, CA). Asparg-val-tyr-ile-his-pro-phe-his-leu (AI) eluted at -11 min. Des-leu1o-angiotensin I eluted at -4.5 min. Asp-arg-val-tyr-ile-his-pro-phe (All) is formed by phes-hisg bond cleavage of AI and elutes at -7.0 min. Asparg-val-tyr is formed by tyr4-iles and phe8-his9 bond cleavage of Al 9 vol 0.02 M TAME). The counting vial was then tightly capped and, after 30 min, the reaction was stopped and the liberated methanol partitioned into the toluene-based cocktail by vigorous shaking. The vials were then counted for 4 min in a liquid scintillation spectrometer. Human urinary kallikrein ofknown activity was used as a quality control in each assay. BTEE hydrolysis was measured by a spectrophotometric assay as described (16) . The assay was standardized with bovine a-chymotrypsin. Lactic dehydrogenase (17) was measured as described.
Kinetic constants were determined using Lineweaver-Burk analysis of the reciprocal of the reaction velocity and substrate concentration.
Enzyme purification. Human lung mast cell chymotrypsin-like enzyme was partially purified by Sephacryl S-200 gel filtration of whole mast cell lysates or from supernatants ofmast cell preparations obtained following challenge with anti-IgE. In either case, enzyme sources were made 3 M NaCI before 2-h incubation on ice to dissociate the activity from insoluble cell constituents and/or proteoglycans. After centrifugation for 15 min at 10,000 g, supernatants were filtered through a 1.6 X 91-cm Sephacryl S-200 column run at 4VC in 0.1 M Tris, pH 7.4, 1.0 M NaCl at 12 ml/h. Fractions of2-ml vol were collected, screened for protein by absorbance at 280 nm, and assessed for activity. Active fractions were pooled and concentrated to starting volume using a positive pressure system (Amicon Corp., Scientific Systems Div., Danvers, MA) and a YM-5 membrane.
Human leukocyte cathepsin G was purified to homogeneity from the granules of fresh human peripheral blood polymorphonuclear leukocytes by Aprotinin-Sepharose affinity chromatography and carboxymethyl cellulose cation exchange chromatography (18, 19) . Human skin chymotryptic proteinase was highly purified from human skin by 2.0 M KCI extraction, Sephacryl S-200 gel filtration, and D-tryptophan methyl ester-Sepharose affinity chromatography (7) . Its concentration was measured by active site titration with tritium-labeled diisopropylfluorophosphate.
Results
Detection of a chymotrypsin-like enzyme in human lung mast cell preparations. Purified human lung mast cell preparations (10-65% pure) were examined for chymotrypsin-like activity by 30-min incubation of 10-,gl samples of whole cell lysates with Al and assay by HPLC for Al conversion to All. In each case, phe8-his9 bond cleaving activity was detected by HPLC identification of the products All and his-leu (Table I) .
The time course of Al conversion by a 65% pure mast cell preparation which contained 5.5 X 10' mast cells/ml was examined by incubating 10 and 25 u1 of the whole cell lysate with Al for various times at 37°C. All formation proceeded rapidly ( Fig. 1 ) and the constituent tetrapeptides of AII, asp-arg-val-tyr and ile-his-pro-phe, were not observed. The dose-response ofAl conversion was studied by incubation of various amounts ofthe same mast cell preparation for 15 min with Al under identical reaction conditions. All generation increased in a dose-depen- (Fig. 2) . The pH optimum of the mast cell preparation Al-converting activity was determined by incubating 10-i1 aliquots of the mast cell lysate with Al for 15 min in various mixtures which differed by 1.0 pH units from 3.5-10.5. The pH optimum was 7.5-9.5 (Fig. 3) Aliquots (10 gl) of the 65% pure mast cell preparation, (5.5 X l0) mast cells/ml, were exposed to each inhibitor (10-' M) for 15 min at 370C before assay of Al conversion. PMSF (10-' M) completely inhibited the All-generating activity (Table II) . Captopril, an inhibitor of the dicarboxylcarboxypeptidase angiotensin-converting enzyme, did not inhibit Al conversion by the mast cell enzyme. Taken together the results indicate that mast cell Al conversion is carried out by a chymotrypsin-like seine endopeptidase which cleaves the phe8-his9 bond of Al.
Localization of the chymotrypsin-like enzyme to the mast cell. Since mast cell preparations contained other cell types, experiments were carried out to identify the cell which contained the chymotrypsin-like Al-converting activity. A preparation of mast cells of >99% purity (106 cells/ml) was examined for Alconverting activity and challenged with goat anti-human IgE antibody. Supernatants from unchallenged and challenged cells and the residual cell lysate were examined for Al-converting activity and for the mast cell secretory granule marker, histamine (Table III) . The chymotrypsin-like activity was detected in the >99% mast cell preparation and was released by IgE-mediated challenge in a manner similar to histamine. Net percent release values of histamine and the chymotrypsin-like activity from nine preparations of human lung mast cells of 10-99% purity were determined following challenge with anti-IgE. Net percent release values for immunologic challenge of each preparation and at all doses of antibody in a dose-response experiment for the chymotrypsin-like activity were plotted against those of histamine (Fig. 4) and the data was analyzed by linear regression. There was a linear relation by regression Separation of the chymotrypsin-like enzyme from mast cell tryptase and relationship to leukocyte cathepsin G and the human skin chymotrypsin-like enzyme. To determine the relationship of the chymotrypsin-like enzyme to human mast cell tryptase, supernatants (n = 4) obtained after IgE-mediated challenge of mast cell preparations were made 3 M NaCl, incubated on ice for 2 h, and then subjected to Sephacryl S-200 gel filtration.
Column fractions were examined for Al conversion and tryptase activity (Fig. 5) . A single region of Al-converting activity with an approximate molecular weight of30,000-35,000 was detected. The activity was distinct from tryptase, which eluted at an apparent mol wt of 145,000. The recovery of angiotensin-converting activity varied from 45 to 50%. Column fractions which contained Al-converting activity were pooled and concentrated and used in subsequent experiments as partially purified chymotrypsin-like enzyme.
Experiments were designed to determine the functional relationship of the human lung mast cell chymotrypsin-like en- (Table IV) . Likewise, the lung mast cell and skin chymotrypsin-like proteinases were distinguished from cathepsin G with respect to susceptibility to LBTI and SBTI. All three enzymes were similarly susceptible to PMSF. Partially purified mast cell chymotrypsin-like enzyme was examined for ability to hydrolyze BTEE, a synthetic substrate of cathepsin G and the skin proteinase. 25-, 50-, and 100-Ml samples of partially purified lung mast cell enzyme displayed BTEE hydrolyzing activity equivalent to 0.095, 0.1875, and 0.350 mg of chymotrypsin. Amounts of each enzyme with identical activities on BTEE were then evaluated for ability to convert Al to All. Cathepsin G, skin chymotryptic proteinase, and lung mast cell enzyme activities were active at neutral pH ( Fig. 3) and is inhibited by PMSF but not by Captopril (Table II) . The chymotryptic activity is apparently preformed as it was detected in whole lysates. It was released by challenge of a 99% pure mast cell preparation with anti-IgE (Table III) and protease release paralleled histamine release. Regression analysis of the net percent release of the enzyme, when plotted against those of histamine, yielded a straight line which passed through the origin (Fig. 4) (Fig. 5) . The enzyme was similar to a chymotrypsin-like enzyme isolated from human skin with respect to susceptibility to inhibitors (Table IV) , relative activity on the synthetic substrate BTEE, and affinity for AI substrate. It was distinguished from leukocyte cathepsin G by the same criteria. The partially purified enzyme displayed limited chymotryptic specificity as it hydrolyzed only the phe8-his9 of Al but failed to hydrolyze the same bond of des-leu1o-AI or the tyr4-ileu5 bond of All (Fig. 6) . Thus, the lung mast enzyme is a previously unrecognized human chymase and is probably identical to the human skin chymotrypsin-like proteinase which is also thought to be mast cell associated (7) .
Chymotrypsin-like proteinases have been previously identified in mast cells from a variety of sources, including rat peritoneum (3, 4) and dog (5) and mouse (22) mastocytoma tissues. In addition such enzymes have been isolated from rat (23, 24) and human (7, 25) skin. The major neutral protease of the rat peritoneal mast cell is rat mast cell proteinase I (chymase) (3, 4) , while tryptase is thought to be the major protein constituent of the human mast cell secretory granule (1) and is present at levels of 10-20 zg/ 106 mast cells (1) . While a chymotrypsin-like activity has been sought in dispersed human lung mast cell preparations using BTEE as substrate (1), the relative inability of the human lung mast cell chymotrypsin-like enzyme to cleave this substrate prevented its detection. The use of Al as substrate made the detection of this activity possible. Available data does not permit quantification ofthe amount ofthe human chymotrypsinlike enzyme in lung mast cells; however, the activity is easily detected in lysates of 103 mast cells using AI as substrate.
The functional role of mast cell enzymes in vivo has not been identified. It is possible that, when released as constituents of the mast cell secretory granule, they may act as mediators so as to directly affect tissue targets, or they may act indirectly to generate bioactivities from fluid phase or tissue substrates. In vitro data suggest that both mechanisms are possible. Human skin chymotrypsin-like proteinase cleavage of the cutaneous epidermal-dermal junction at the lamina lucida (26) is an example of a direct action of a mast cell enzyme, while mast cell kinin-generating activity (27) and tryptase cleavage of the third component of complement (28) and fibrinogen (29) illustrate indirect actions of mast cell enzymes. If the human mast cell chymase is indeed identical to the human skin chymotrypsinlike proteinase, the Km and K., for AI conversion would be 6.6 X 10-5 M and 50 s-', respectively (8) . These kinetics are consistent with a reaction of potential biologic significance. This pathway may then provide a unique mechanism through which the vasoactive peptide All may be generated in perivascular sites in close proximity to vascular smooth muscle targets. Such extra vascular pathways for the generation of vasoactive peptides may provide a hitherto little appreciated mechanism for control of local tissue blood flow.
